BCDA BioCardia, Inc.

NEUTRAL Impact: 2/10 PRESS-RELEASE
Horizon days Filed May 11, 2026 Processed 9d 18h ago Wire GlobeNewswire
Press release: earnings
Latest settled — T+5d
BCDA ▼ -19.64% at T+5d
NEUTRAL call ✗ call lost -19.64% · α vs SPY -19.72% · entry $1.12 → $0.9000
Next anchor: T+20d in 19d
Currently $0.9215 · -17.72% from $1.12 entry
Entry anchored
May 11, 2026
via day open
T+1d
0.00%
call 0.00% · α -0.54%
$1.12
settled 9d ago
T+5d
-19.64%
call -19.64% · α -19.72%
$0.9000
settled 3d ago
T+20d
call — · α —
in 19d
T+60d
call — · α —
in 3mo

Price Chart

Loading chart...

Executive Summary

BioCardia announced it will report Q1 2026 financial results on May 15, 2026. The press release contains no actual financial data for the current period, only a conference call notice. The company's Q4 2025 EPS of -$0.06 beat consensus by 64.7%, but the stock has historically not responded well to prior bullish calls, with a 40% win rate and negative average returns.

Actionable Insight

Monitor the Q1 2026 earnings call on May 15 for actual financial results and any guidance updates. Given the micro-cap status and historical poor stock response to bullish events, any positive surprise may already be priced in or face selling pressure.

Key Facts

  • BioCardia will report Q1 2026 financial results on May 15, 2026 via conference call.
  • No financial results for the current period are disclosed in this press release.
  • Q4 2025 EPS was -$0.06, beating consensus of -$0.17 by 64.7%.
  • Market cap is $12M with 88% analyst bullish sentiment.
  • Recent insider activity includes 3 buys totaling $7K in the last 30 days.
  • Historical performance shows a 40% win rate at T+20 with negative average returns.

Financial Impact

No current period financial data disclosed; Q4 2025 EPS beat by 64.7%.

eps

Risk Factors

  • No current financial data disclosed, creating uncertainty.
  • Micro-cap stock with low liquidity and high volatility.
  • Historical poor performance of prior bullish calls on this ticker.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (8 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3292408
11 reports for BCDA
Performance horizon
29% Hit rate 2 of 7 directional calls best @ T+20▲ +10.08%Apr 15, 2026
Filters
Rows
Reports for BCDA — sortable, filterable
Type Now
May 15, 2026
6d ago
8-K
MIXED ★ 6/10
$1.09 awaiting T+5awaiting T+5$0.9215 (−15.07%)
May 15, 2026
6d ago
Press Release
MIXED ★ 6/10
$1.09 awaiting T+5awaiting T+5$0.9215 (−15.07%)
May 11, 2026
9d ago
Press Release
NEUTRAL ★ 2/10
$1.12 $0.9000▼ −19.64%▼ −19.72%$0.9215 (−17.72%)
May 8, 2026
13d ago
8-K
BULLISH ★ 6/10
$1.11 $1.09▼ −1.80%▼ −3.27%$0.9215 (−16.98%)
Apr 28, 2026
23d ago
8-K
NEUTRAL ★ 2/10
$1.14 $1.13▼ −0.88%▼ −2.57%$0.9215 (−19.17%)
Apr 20, 2026
4w ago
Press Release
BULLISH ★ 8/10
$1.25 $1.16▼ −7.20%▼ −8.11%$0.9215 (−26.28%)
Apr 15, 2026
5w ago
8-K
BEARISH ★ 8/10
$1.19 $1.17▲ +1.68%▲ +2.66%$0.9215 (+22.56%)
Apr 2, 2026
7w ago
Press Release
BULLISH ★ 8/10
$1.20 $1.18▼ −1.67%▼ −5.29%$0.9215 (−23.21%)
Apr 2, 2026
7w ago
8-K
BULLISH ★ 7/10
$1.20 $1.18▼ −1.67%▼ −5.29%$0.9215 (−23.21%)
Mar 24, 2026
8w ago
Press Release
BEARISH ★ 6/10
$1.20 $1.16▲ +3.33%▲ +3.09%$0.9215 (+23.21%)
Showing 10 of 11

US Market Status

Market Open — Closes in 3h 52m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access